Safety and efficacy of autoantigen ‐specific therapy with 2 doses of alum‐formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: A randomized clinical trial

ConclusionsGAD‐Alum as a subcutaneous prime and boost injection was safe in prediabetic young children but did not affect progression to type 1 diabetes. The safety of GAD‐Alum should prove useful in future prevention studies.

Source: Pediatric Diabetes - November 24, 2017 Category: Endocrinology Authors: Helena Elding Larsson, Markus Lundgren, Berglind Jonsdottir, David Cuthbertson, Jeffrey Krischer, Tags: ORIGINAL ARTICLE Source Type: research